Buprenorphine Access Patterns from 2019 to 2025
Recent data from the Centers for Disease Control and Prevention indicates significant shifts in how buprenorphine reached patients across the United States between 2019 and 2025. Buprenorphine remains a vital tool for managing opioid use disorder, yet the pathways for obtaining this treatment vary between urban and rural settings. Retail pharmacies saw dispensing rates rise between 2019 and 2021 before a steady decline through 2025. Despite this national downturn, rural counties maintained higher dispensing rates than urban counterparts throughout the entire period.
Pharmacy availability increased across the board. In rural areas, 80 percent of pharmacies reported dispensing buprenorphine by 2025, a jump from 64.9 percent in 2019. Urban pharmacies followed a similar upward trend, reaching 72.4 percent availability by the end of the study. These figures suggest that while pharmacies remain the primary access point for rural patients, other healthcare infrastructure struggles to match this reach. The reliance on retail outlets likely fills a gap left by the scarcity of specialized addiction treatment centers in smaller communities.
Emergency Department Trends and Clinical Adoption
Emergency departments serve as an alternative point of entry for those seeking treatment, though adoption rates show a distinct urban-rural split. Urban hospitals led the way in integrating buprenorphine into their emergency protocols. By 2025, nearly one-third of urban emergency departments had adopted buprenorphine protocols, compared to roughly 10 percent of rural facilities. This disparity highlights the challenges rural hospitals face regarding staffing, behavioral health support, and care coordination infrastructure.
Administrations per 1,000 emergency department visits climbed in both settings, but the concentration of services remains heavier in urban hospitals. When focusing specifically on visits related to opioid use disorder or nonfatal overdose, the rate of buprenorphine administration grew in both regions. Urban centers reached 111.1 administrations per 1,000 such visits by 2025, while rural hospitals recorded 103.3. While the raw administration numbers for specific opioid-related visits are closer, the broader adoption of routine protocols still lags in rural medical facilities.
Workforce Capacity and Future Implications
Policy changes significantly altered the landscape of buprenorphine prescribing. The elimination of federal waiver requirements in December 2022 contributed to a wider distribution of prescribing capacity. While the total number of prescribers increased, the number of patients and prescriptions per individual prescriber dropped significantly. This shift signals a transition away from a small group of high-volume clinicians toward a more decentralized model of care.
Prescribing remains heavily concentrated among a top tier of high-volume providers. In urban areas, the top 10 percent of prescribers accounted for 84.8 percent of all dispensed buprenorphine prescriptions in 2025, while rural areas saw a similar concentration at 81 percent. The increase in average days’ supply per prescription, which grew from roughly 17 days to 22 days, suggests that providers are shifting toward longer-term maintenance strategies. This change could improve continuity for patients who face travel or logistical barriers.
Broadening access to treatment requires addressing these persistent geographic discrepancies. Sustaining telehealth flexibilities remains a primary recommendation for rural public health. Because specialized care is often physically distant for rural populations, the continued use of remote prescribing and support tools is critical. Public health experts point to the success of pharmacy dispensing as a model to build upon while noting that emergency departments need more institutional support to mirror this availability. Future efforts must prioritize local workforce development and infrastructure to bridge the remaining gaps in rural addiction medicine.